In March of this year, the National Institute for Health and Care Excellence (NICE) declared that patients should not be allowed access to Enhertu due to the medication’s lack of value for the money.
However, Sir Pascal Soriot expressed his disappointment at the decision, citing among other reasons the fact that Enhertu had been made available to patients in 17 other European nations, including NHS patients in Scotland, and that it was expected to have affected at least 1,000 individuals to far.
He stated to News that “severity scoring is a methodology used by NICE that makes it difficult to obtain innovative medicines.”
Most people consider it to be a serious illness. I’m confident that patients would describe it as a serious illness. However, NICE determined that the illness is fairly severe. Although it appears to be a technical element, willingness to pay is a key factor in its importance.
As a result, 17 European nations have chosen to pay Enhertu for breast cancer that has spread to other areas of their countries. Romania has since compensated. In the United Kingdom, Scotland has chosen to compensate Enhertu for metastatic breast cancer, albeit employing a different methodology.
